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Abstract
Metastasis is responsible for most deaths due to malignant melanoma. The clinical significance of micrometas-
tases in the lymph is a hotly debated topic, but an improved understanding of the lymphatic spread of cancer
remains important for improving cancer survival. Cellular magnetic resonance imaging (MRI) is a newly emerging
field of imaging research that is expected to have a large impact on cancer research. In this study, we demonstrate
the cellular MRI technology required to reliably image the lymphatic system in mice and to detect iron-labeled
metastatic melanoma cells within the mouse lymph nodes. Melanoma cells were implanted directly into the in-
guinal lymph nodes in mice, and micro-MRI was performed using a customized 1.5-T clinical MRI system. We
show cell detection of as few as 100 iron-labeled cells within the lymph node, with injections of larger cell numbers
producing increasingly obvious regions of signal void. In addition, we show that cellular MRI allows monitoring of
the fate of these cells over time as they develop into intranodal tumors. This technology will allow noninvasive
investigations of cellular events in cancer metastasis within an entire animal and will facilitate progress in under-
standing the mechanisms of metastasis within the lymphatic system.
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Introduction
Melanoma is a form of skin cancer with 160,000 new cases reported
annually worldwide [1]. It is diagnosed most frequently in Caucasian
males and is particularly common in populations living in sunny cli-
mates [2]. According to a World Health Organization report, approx-
imately 48,000 deaths due to malignant melanoma are registered
annually [3]. Most of these deaths are due to metastatic infiltration
of distant organ tissues [4].
When staging melanoma, the critical question is whether tumor
cells have metastasized to other tissues. For localized disease, surgical
resection of the primary tumor before it achieves a thickness of more
than 1 mm is generally a very successful therapy [5]. If the melanoma
has spread to the lymph nodes, then the most predictive factor is the
number of tumor-positive nodes [6]. The extent of malignancy within
a node is also important; metastases in which malignancy is only mi-
croscopic have a more favorable prognosis than macrometastases [7].
However, once the disease has metastasized beyond the nodes to dis-
tant organ tissues, the cancer is generally considered incurable, and a
5-year survival rate is less than 10% [8].
Cancer metastasizes through a series of sequential, interrelated
steps, each of which is rate limiting [9]. These include: 1) invasion
of cancer cells into the lymph vessels or bloodstream or delivery to
organs, such as the lymph nodes, liver, lung, bone, or brain; 2) ex-
travasation of cells into the organ parenchyma; 3) cell proliferation
to form secondary (late-stage) tumors; and 4) development of new
blood vessels to sustain continued growth. Despite many years of lab-
oratory and clinical research, late-stage melanoma treatments have
not been very successful. Therefore, a noninvasive method to detect
and screen for earlier and smaller lymph-node micrometastases may
greatly reduce the mortality rate associated with melanoma.
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To study melanoma, metastastic mouse models have been devel-
oped using both mouse-derived and human-derived melanoma cell
lines [10–12]. Preclinical models are typically characterized by gross
lesion description and histology. Unfortunately, all of these methods
are invasive and require that animals be sacrificed to collect the data,
prohibiting longitudinal measurements in the same animal. Sensitive
and specific noninvasive imaging techniques are key to gaining infor-
mation about the fate of cancer cells and metastasis in vivo.
A number of in vivo imaging modalities can assess tumor develop-
ment in preclinical animal models. These include optical techniques,
such as bioluminescence imaging [13] and intravital video microscopy
[14], computed tomography [15], ultrasound (US) [16], nuclear im-
aging techniques, such as positron emission tomography [17] and
single-photon emission computed tomography [18], and magnetic reso-
nance imaging (MRI) [19].
High-resolution MRI provides an exceptional imaging modality
for studying tumor progression. Magnetic resonance imaging can
provide three-dimensional (3D), detailed anatomic information in
a noninvasive manner, with current micro-MRI techniques capable
of in vivo resolution on the order of tens of micrometers [20,21].
Unlike histologic analyses, which provide only a snapshot of the over-
all process, MRI can provide a dynamic view of disease progression,
delivers results in real time, requires fewer animals, and is free from
sectioning-related artifacts. Thus, MRI may provide a more complete
picture of the overall biologic process under investigation.
Cellular MRI is a young field of imaging research that combines the
high resolution of micro-MRI with sensitive iron oxide–based contrast
agents for cell and receptor labeling [22,23]. This combination allows
for the investigation of biologic processes at the cellular level. The pres-
ence of this magnetic label in cells causes a distortion in the magnetic
field and leads to signal hypointensities (negative contrast) in MR
images [24]. The development of a broad range of iron oxide contrast
agents, as well as cell labeling techniques [25–28], has stimulated the
development of a range of applications for MRI cell tracking. A variety
of iron oxide–based labels are available including superparamagnetic
iron oxide particles (SPIO), ultrasmall iron oxide agents (USPIO)
and micrometer-sized iron oxide particles (MPIO). Micrometer-sized
iron oxide particles have advantages over SPIO or USPIO for labeling
cancer cells. Micrometer-sized iron oxide particles contain more iron
and offer the possibility of greatly increasing iron content in labeled
cells. The polymer coating of MPIO should be inert to the cell, allow-
ing long-term studies of labeled cells and their progeny [29]. Cancer
cells take up MPIO rapidly and efficiently and, even at high iron load-
ings, are not toxic or known to adversely affect cancer cell function
[30]. In addition, MPIO can be purchased with a fluorophore that
allows for correlative microscopy.
Cellular MRI offers the opportunity for early detection of small num-
bers of metastatic cells and also provides the opportunity for studying
micrometastatic processes in their earliest developmental stages in the tar-
get organs of interest. In this study, we demonstrate that cellularMRI can
be used to reliably image the lymphatic system in mice and to detect
iron-labeled metastatic melanoma cells within the mouse lymph nodes.
Materials and Methods
Cell Culture and MPIO Labeling
Murine B16F10 melanoma cells were chosen because of their high
metastatic potential to regional lymph nodes [31]. B16F10 melanoma
cells were maintained in Dulbecco’s modified Eagle’s medium–high
glucose media (Invitrogen, Ontario, Canada) containing 10% FBS
at 37°C and 5% CO2. For MPIO labeling, 5 × 10
5 cells were plated
in six-well dishes, supplemented with media and allowed to adhere for
24 hours. MPIO beads, 5.0 × 108 (0.9 μm in diameter, ∼63% mag-
netite) (Bangs Laboratories, Fishers, IN), were added to 2 ml of media
in each well of a six-well dish, and cells were incubated for an addi-
tional 24 hours. Cells were washed thoroughly with PBS to remove
unincorporated MPIO, and cell viability was assessed using Trypan
blue exclusion. To quantify the extent of MPIO labeling, 2 × 106 cells
were suspended in gelatin and aliquoted into microcentrifuge tubes for
the quantification of cellular iron uptake. The mean cellular MPIO
content, expressed in picogram of Fe per cell, was assessed by induc-
tively coupled plasma–mass spectroscopy (ICP-MS).
To monitor the iron concentration in dividing cells, 1 million B16F10
cells were added to 50-ml tissue culture flasks and allowed to adhere
and propagate. A day after plating, while cells were in logarithmic
growth, MPIO were added to the media of half the flasks, whereas
other flasks remained unlabeled as controls. Cells were incubated with
the label for 24 hours then harvested, washed, and counted. Aliquots
of cells from both groups were collected for iron quantification by
ICP-MS and for visualization of beads under the microscope. One
million labeled or unlabeled cells were then replated and allowed to
propagate further. Cells were collected for quantification and further
subcultured on days 3, 5, 10, and 13 postlabeling.
Animal Model
To standardize the probability of tumor development and cellular
burden in the lymph node, cells were injected directly into the ingui-
nal lymph node of female C57Bl/6 mice (17 to 20 g) (Charles River
Laboratories, Wilmington, MA). Mice were cared for in accordance
with the standards of the Canadian Council on Animal Care and un-
der an approved protocol of the University of Western Ontario’s Coun-
cil on Animal Care. A superficial skin incision, approximately 1 cm in
length, was made in the lower right abdominal quadrant of anesthe-
tized mice. The skin was inverted to expose the right inguinal lymph
node. A 5-μl volume of B16F10 cells was then slowly injected using a
Hamilton syringe and an investigational microneedle (BD, Franklin
Lakes, NJ). The dermal incision was closed with VetBond Tissue Ad-
hesive (3M, St. Paul, MN). Mice received either 100 (n = 5), 1000
(n = 10), or 10,000 MPIO-labeled cells (n = 20). Control groups re-
ceived saline (n = 2) or unlabeled cells (10,000, n = 3).
Magnetic Resonance Imaging
All MRI scans was performed on a 1.5-T GE CV/i whole-body
clinical MR scanner (General Electric, Mississauga, Canada) using a
custom-built gradient coil (inner diameter, 17.5 cm; maximum gradi-
ent strength, 500 mT/m; and peak slew rate, 3000 T/m per second)
and a custom-built solenoidal mouse body radiofrequency coil. The
radiofrequency coil was built to permit the simultaneous imaging of in-
guinal, popliteal, and axial lymph nodes, and it had a diameter of 4 cm
and a length of 4.5 cm. Mice were anesthetized with isofluorane (1% in
100% oxygen) using a nose cone with vacuum for scavenging. In vivo
images were obtained using a 3D balanced steady-state free precession
imaging sequence [Fast Imaging Employing Steady State Acquisition
(FIESTA) on the GE system]. A number of sequence parameters were
optimized to achieve high-quality, mouse whole-body images including
the bandwidth (BW), repetition time (TR), echo time (TE), and flip
angle. The optimized sequence employed TR/TE = 9.1/4.5 milliseconds,
flip angle = 30°, BW = ±21 kHz, two signal averages, and phase cycling.
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Images were acquired at either 200-μm3 isotropic spatial resolution
with two signal averages (34 minutes) or at 100-μm3 isotropic spatial
resolution with eight signal averages (68 minutes). Zero filling was
used to give an interpolated voxel dimension of 120 × 120 in-plane.
Two imaging experiments were performed: a longitudinal study
and a cross-sectional study. In the longitudinal study, mice were in-
jected with different numbers of labeled cells (100 cells, n = 5; 1000
cells, n = 10; 10,000 cells, n = 5) imaged repeatedly on days 1, 4, 7,
14, and 22 postinjection and then sacrificed for histological analysis.
In the cross-sectional study, five groups of three mice (total, n = 15)
were injected with 10,000 labeled cells, and the separate groups of
mice were imaged once at five different time points (days 1, 8, 10,
12, and 15) and then sacrificed for histological analysis.
Image Processing
During the imaging optimization steps, image quality was measured
by calculating the node signal-to-noise ratio (SNR) and the contrast-
to-noise ratio between the lymph node and the fat. The average con-
trast from regions of signal loss was measured using an image analysis
package (ImageJ; National Institutes of Health, Bethesda, MD). Signal
void contrast was expressed as the percent signal drop compared to
background node tissue and was calculated by taking the signal differ-
ence between background node tissue and a region of interest within
the region of signal loss, dividing by the background signal, and mul-
tiplying this fractional signal loss by 100%. The number and size of
lymph node and tumors were measured using another image analysis
package (VG Studio Max, Heidelberg, Germany).
Histology
Lymph nodes and tumors were removed at the end of the experiment
and fixed in 10%buffered formalin. Paraffin-embedded lymph nodes and
tumors were sectioned at 10-μm thickness. Staining methods included
hematoxylin and eosin (H&E) to visualize tumor and node morphology,
S100 (polyclonal antibody, Z311; Dako, Ontario, Canada) to identify
melanoma cells, and Perls’ Prussian blue (PPB) staining to visualize iron.
Results
In Vivo MRI of Mouse Lymph Nodes
Figure 1 shows representative in vivo coronal FIESTA image slices
through the mouse body in a control mouse that did not receive any
injection. The image resolution is 200 μm in each of the three di-
mensions. In these data sets, the axillary, inguinal, and popliteal
lymph nodes can all be readily visualized, although not all in the
same image slice. At least 10 different lymph nodes could be easily
identified in the FIESTA images.
The normal lymph nodes are clearly visualized as structures within
the fat pad, due to the very high contrast between the normal node
and the surrounding fat; the mean fat–node contrast-to-noise ratio
measured for normal lymph nodes (n = 10) was 72. The mean in-
guinal node SNR was 35. The volumes of the normal axillary, ingui-
nal, and popliteal lymph nodes were measured to be 3.54 (±0.31),
3.20 (±0.81), and 0.79 (±0.36) mm3, respectively.
Part of the FIESTA sequence optimization involved varying the
receiver bandwidth and timing parameters. As the BW in the FIESTA
imaging sequence is changed, the TR/TE changes. With spatial reso-
lution held at 100 × 100 × 200 m3, varying the BW between ±16
and ±41 kHz produces TR/TE values of 9.0/4.5 to 4.0/2.3 milli-
seconds, respectively. Increasing the BW (shorter timing parameters
TR/TE) will reduce the scan time but will also reduce the SNR.
In addition, the shorter TE reduces the contrast generated by iron-
labeled cells. The choice of BW for live mouse imaging must consider
all of these factors. The optimal BWand timing parameters, for mouse
body FIESTA imaging, were determined to be ±21 kHz with TR/TE of
9.1/4.5 milliseconds.
Phase cycling was used to minimize banding artifacts that are pro-
duced with the FIESTA imaging sequence and appear as unwanted
regions of low signal intensity or shadowing near tissue interfaces.
Images of a control mouse, which did not receive any injection, de-
picting the effect of employing phase cycling are shown in Figure 2.
Without phase cycling, significant banding artifacts are produced in
Figure 1. In vivo FIESTA images of the mouse body obtained with 200 × 200 × 200 μm3 spatial resolution and a 34-minute scan time.
(A–C) Three coronal FIESTA image slices are shown (cropped) from the same 3D data set and the same animal. Different lymph nodes
appear in different MR slices. (A) Right axillary node (arrow). H indicates the direction of head; L, lung; SC, spinal cord. (B) Both inguinal
nodes (white arrows) and a lymphatic vessel (yellow arrow). B indicates the bladder; I, intestines. (C) Both popliteal nodes (white ar-
rows). M indicates the muscle. (D) At least 10 different lymph nodes could be easily identified in the FIESTA images. These 3D images
can be rendered for easy visualization of lymph nodes of interest in the mouse, making it possible to survey the lymphatic system for
cancer cells. In this rendering, the nodes are purple, the heart is red, lungs are white, the kidneys are blue, and the bladder is yellow.
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the mouse body where many different tissue interfaces exist (Fig-
ure 2A, arrows). Banding at the body surface is especially detrimental
to imaging of lymph nodes because superficial nodes are typically ad-
herent to the skin’s surface. With phase cycling implemented, the
ability to visualize the inguinal lymph node (arrow) is improved dra-
matically (Figure 2B).
B16F10 Cell Labeling
B16F10 cells readily take up the MPIO label while maintaining
high viability. The labeling efficiency was 100%; however, the extent
of iron labeling per cell varied (Figure 3B). Standard methods for
measuring iron content provide only the average amount of iron
per cell; the mean iron loading, measured by ICP-MS, was 35 pg
of Fe/cell. The doubling time of both the MPIO-labeled and un-
labeled cells was equivalent at approximately 20 hours. Trypan blue
staining revealed no difference in cell viability for MPIO-labeled cells
versus unlabeled cells (not shown). The serial photomicrographs in
Figure 3B show the presence of the beads (unstained, brown) in
B16F10 cells and demonstrate the disappearance of intracellular iron
from the rapidly dividing cells. There appeared to be a complete loss
of detectable iron by day 5, corresponding to the sixth generation of
daughter cells. Iron content analysis by ICP-MS was consistent with
microscopy results also revealing the reduction of cellular iron to
background levels (Figure 3A).
Figure 2. Coronal in vivo FIESTA images of a normal mouse body (no cells injected) acquired with and without radiofrequency phase
cycling. (A) Phase cycling is not used. Significant banding artifacts are produced in the mouse body at existing tissue interfaces (arrows).
(B) The ability to visualize the inguinal lymph node (arrow) is improved dramatically with phase cycling implemented. H indicates the
direction of the mouse head.
Figure 3. (A) Iron content measurements by ICP-MS and (B) photomicrographs of unstained MPIO-labeled B16F10 cells show the rapid
disappearance of iron in dividing cells.
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The microinjection of cells into the inguinal lymph node did not
adversely affect the cell viability or alter the observed nodal structure.
This is confirmed by the finding of 95 ± 4.4% cell viability after the
passage of cells through the microneedle system. In addition, we have
observed proper lymphatic flow into and out of the node, 24 hours
following the cell injection, using Evan’s blue dye (data not shown).
In Vivo MRI of MPIO Labeled Melanoma Cells:
Longitudinal Imaging
MRI appearance of labeled cells. MPIO-labeled melanoma cells
appeared as regions of signal loss in FIESTA images of the injected
inguinal nodes. In Figure 4, MR images of the inguinal lymph nodes,
on day 1 postinjection, are shown cropped and enlarged: (A) saline
injection, (B) 100 cells, (C ) 1000 cells, and (D) 10,000 cells. These
images were acquired in the coronal plane at a spatial resolution of
200 μm3. Blinded observers could not routinely distinguish between
images of lymph nodes injected with saline and lymph nodes injected
with 100 MPIO-labeled cells. Distinct regions of signal loss were
consistently observed within lymph nodes injected with 1000 cells,
and the region of signal loss was further increased in the lymph nodes
injected with 10,000 cells. This was expected because the MPIO
within the cell affects the MR signal over a large volume surrounding
the cell, i.e., a so-called blooming effect.
In a subsequent group of mice injected with 100 cells (n = 5),
images were acquired in the axial plane with a higher spatial reso-
lution and a longer scan time. Figure 5 shows that in these images,
with 100-μm3 spatial resolution, small focal patterns of signal loss
could be observed. This observation was made in fours (80%) of five
mice injected with 100 MPIO-labeled melanoma cells, and the signal
loss persisted for 22 days postinjection. Figure 5C shows that PPB-
positive cells are present in the implanted node at day 22. These cells
appear to be located mainly in the center of the node. Some cells can
be detected that are positive for both iron and melanin (Figure 5D).
Signal loss was not observed in nodes that were not injected with cells
or in nodes injected with saline or unlabeled cells (not shown).
Tumor development. Tumor growth could be detected in the MR
images, on day 14 postinjection, in 5 of the 10 mice injected with
1000 cells. In the five mice injected with 10,000 cells, tumors were
visualized in two by day 7 and in all by day 14. Tumor growth was
not observed with MRI in mice injected with 100 cells. The evolu-
tion of tumor growth was monitored using MRI, and Figure 6 shows
representative time course FIESTA images of mice injected with
1000 (Figure 6A) or 10,000 (Figure 6B) MPIO-labeled melanoma
cells. In Figure 6A, the spatial distribution of the signal loss within
the node appears similar over time as the tumor grows, but morpho-
logic changes in nodal structure are observed as early as day 4 post-
injection. On day 1, at the higher 10,000-cell load (Figure 6B), there
is a greater blooming artifact, likely due to the larger number of cells,
and therefore, iron in the sample. Morphologic changes remain vis-
ible early on, and on equivalent days, the tumors are consistently
larger than those in the 1000-cell cohort. The appearance of tumors
in this group was similar in all mice with signal loss becoming dis-
persed throughout the tumor tissue over time, with a multilobular
structure and signal hyperintensity (brightness) appearing by day 22.
In Vivo MRI of MPIO Labeled Melanoma Cells:
Cross-Sectional Study
In mice imaged at day 1 postinjection, signal loss was observed in
the nodes of the three mice injected at the 10,000-cell load. In each
case, this appeared as a large region of signal loss at the inguinal node
that partially or completely interfered with visualization of the node
itself. These results were consistent with, and predicted by, the ob-
servations of mice from the previous longitudinal experiment. In
mice sacrificed at day 1 postinjection, no pigmentation was observed.
In mice imaged on day 8 postinjection, signal loss was again observed
in all (three) animals. At sacrifice, a small focal region of pigmenta-
tion was typically observed in the excised tissue.
Figure 4. Coronal in vivo FIESTA images of mouse inguinal lymph nodes acquired with 200 × 200 × 200 μm3 spatial resolution in 34 minutes
(cropped and enlarged). Images were acquired on day 1 postinjection of (A) saline, (B) 100 MPIO-labeled cells, (C) 1000 MPIO-labeled cells,
and (D) 10,000 MPIO-labeled cells. Regions of signal loss are apparent in C and D (arrows).
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In mice imaged on day 10 postinjection, the MR scan’s appearance
was more variable. Signal loss was only observed in two of three mice.
In these mice, the node appeared enlarged, tumor growth was evident,
and signal loss was dispersed throughout the tumor. At dissection,
the nodes appeared up to twice the normal size, and the exterior
was darkly pigmented. In the one mouse that did not show signal loss
in the node, the node appeared normal in size and color at dissection.
The MR scan’s appearance of mice imaged on day 12 postinjection
was also variable. Signal loss was observed in all three mice. In one
mouse, a large tumor was obvious at the node. The signal loss was
dispersed throughout the node, and at dissection, the tumor was ap-
proximately four times the size of the normal node and darkly pig-
mented. In two of three mice, signal loss was observed in the images
but the nodes appeared normal in size. At dissection, the nodes ap-
peared normal in size and pigmented. Large tumors were obvious in
the images of mice on days 15 and 22 postinjection. Signal loss was
observed in all mice and was dispersed throughout the tumor. Nodes
dissected at days 15 and 22 after the cell injection showed obvious
tumor growth with variable pigmentation.
Figure 7 shows representative images of mice at days 1, 15, and 22
postinjection and corresponding histology. In Figure 7A, signal loss is
visible in the inguinal node at day 1. In Figure 7B, a representative
FIESTA image of a mouse at day 15 postinjection shows a heteroge-
neous pattern of signal loss within the developing tumor that is more
than twice the normal size of the inguinal node. In Figure 7C, a rep-
resentative FIESTA image of a mouse that received an injection of
unlabeled cells is shown at day 15; the unlabeled cells were injected
on the opposite side. Note that signal loss is not observed in tumors
developing from unlabeled melanoma cells (arrow). In Figure 7D, a
representative FIESTA image of a mouse at day 22 postinjection
shows a very large tumor with a heterogeneous pattern of signal loss
and hyperintensity. Some banding artifacts are visible (black arrows),
Figure 5. Axial in vivo FIESTA images of the inguinal lymph nodes of a mouse acquired with 100 × 100 × 100 μm3 spatial resolution in
68 minutes. The mouse was injected with 100 MPIO-labeled cells, and the images were acquired on (A) days 4 and (B) 22 postinjection.
Small focal regions of signal loss within the node persist over this time course. No tumor growth was evident at dissection. (C) PPB
staining (original magnification, ×40) of this node at day 22 shows the existence of iron-positive cells. (D) At higher magnification
(×100), cells that are PPB-positive and have brown pigmentation, which indicates melanin, can be identified.
Figure 6. Coronal in vivo FIESTA images of mouse inguinal lymph nodes (cropped and enlarged). Monitoring the growth of tumors from
iron-labeled melanoma cells postinjected with (A, top row) 1000 or (B, bottom row) 10,000 cells. The signal loss caused by the iron-labeled
melanoma cells is evident at day 1 postinjection (arrows) and persists as the tumor develops between days 1 and 14 postinjection.
212 Cellular MRI of Cancer in Mouse Lymphatic System Foster et al. Neoplasia Vol. 10, No. 3, 2008
at the edge of the mouse body, caused by nonoptimal loading of the
radiofrequency coil with the mouse, now with a large tumor. Perls’
Prussian blue–stained sections of the node at day 1 indicate the pres-
ence of iron-labeled cells within the node parenchyma (Figure 7E ).
Perls’ Prussian blue–stained section of the nodal tumor developing at
day 15 shows that iron can still be detected in some cells at this late
time point (Figure 7F ). S100, shown here for the day 15 example
with unlabeled cells, was useful for identifying melanoma cells within
the tumor cell mass (Figure 7G, diffuse cytoplasmic brown staining). In
Figure 7H, H&E staining shows a tumor at day 22, depicting bands
Figure 7. Images of mice, injected with 10,000 cells, and imaged on (A) day 1, (B, C) 15, or (D) 22 postinjection before sacrifice for
histological analysis. (A) Coronal FIESTA image of mouse injected with iron-labeled cells shows the region of signal loss on one side
of the node on day 1 (arrow). On dissection, the node had a small focal dark spot on one side. (B) Coronal FIESTA image of mouse
injected with iron-labeled cells shows a distinct pattern of signal loss within the developing nodal tumor on day 15 (arrow). The node is
approximately twice the normal size. (C) Coronal FIESTA image of mouse injected with unlabeled cells shows a homogeneous signal
with no signal loss within the developing intranodal tumor on day 15 (arrow). (D) Coronal FIESTA image of mouse injected with iron-
labeled cells shows a heterogeneous signal within the tumor on day 22 (arrow) with regions of signal hyperintensity. (E) PPB staining of
the node from day 1 shows iron-positive cells invading the node tissue (original magnification, ×10). (F) PPB staining of the node from
day 15 (image in B) shows iron-positive cells invading the node tissue (original magnification, ×40). (G) S100 staining of the tumor in C
shows positive melanoma cells within the tumor cell mass appearing as regions of diffuse, brown cytoplasmic staining (original mag-
nification, ×40). (H) H&E staining shows that, at day 22, the tumor exhibited bands of necrotic tumor cells, with surviving tumor cells
centered around the vascular structures, suggesting that ischemia was the mechanism driving cell death (original magnification, ×4).
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of necrotic tumor cells, with surviving tumor cells centered around
vascular structures, suggesting that ischemia was the mechanism driv-
ing cell death.
Although only the inguinal lymph nodes were imaged in this study,
other nodes were examined at dissection. In 3 of 15 mice injected with
10,000 labeled cells, the brown pigmentation of melanoma cells was
detected on the ipsilateral axillary node, indicating the occurrence of
metastatic trafficking and progression.
Discussion
Many primary malignancies spread through the lymphatic system.
The presence of metastases in sentinel lymph nodes and other nodes
within the regional bed provide clinically important information for
tumor staging, choice of treatment, and prediction of patient out-
comes [32,33]. Tumor cells passing through, or residing in, lymph
nodes may provide a reservoir of cells leading to distant, lethal me-
tastases. The clinical significance of micrometastases in the lymph is a
hotly debated topic, but an improved understanding of the lymphatic
spread of cancer remains important for improving cancer survival.
Advances toward understanding the interactions between tumor cells
and the lymphatic system have been, in part, limited by the lack of
suitable noninvasive assays and experimental models.
Recently, we developed MRI hardware and optimized pulse se-
quence technology to allow the detection of single cells, labeled with
MPIO particles, in vivo in mouse brain [34,35]. The establishment
of this single-cell detection sensitivity coupled with an ability to pro-
duce images at high spatial resolution (∼100-μm voxel size in each of
three dimensions) makes cellular MRI a strong in vivo imaging mo-
dality for studying cancer metastasis. Here, we report the first appli-
cation of in vivo cellular MRI technology for the direct detection of
metastatic melanoma cells in the lymphatic system. We have demon-
strated that high-resolution MRI can be used to reliably image the
lymph nodes in a mouse model of regional malignant disease and
to detect and monitor prelabeled tumor cells within the lymph nodes
at levels leading to progressive disease.
The direct intranodal injection of metastatic melanoma cells pro-
vides a model system for investigating regional tumor growth, cellular
trafficking, and micrometastatic progression. Although the direct im-
plantation of cells into the inguinal lymph node bypasses the normal
steps in the progression of metastasis, this model had certain benefits.
One advantage is that it creates a more reproducible research model.
By injecting a known number of cells into a lymph node, we ensure
that each animal is starting from a similar challenge state. This is im-
portant when comparing animals in an imaging study. Because nat-
ural metastatic progression is more varied, we would initially require
many additional challenged animals to generate enough at a similar
stage for a single study. So by using direct nodal injections, we in-
crease repeatability and reduce animal use in each study.
Before this study, we compared the intranodal injection of mela-
noma cells to a subcutaneous injection of cells into the flank, a more
commonly used model that is generally considered to better represent
spontaneous metastasis. The two models produced similar results.
Briefly, six mice received a subcutaneous injection of 10,000 B16F10
cells and six mice received an injection of 10,000 B16F10 cells directly
into the inguinal node. Tumors grew at the site of implantation in all
mice. Metastasis to regional lymph nodes was observed (on day 28
postmortem) in three of six mice with the subcutaneous injections
and in four of six mice with the intranodal injections. The average
weight of the nodal tumors was 2.42 g, and the average weight of
the subcutaneous tumors was 4.99 g. The imaging results were also
similar; that is, iron-labeled cells were detected at the implantation site
and signal loss became dispersed in growing tumors with time. The
problem with the subcutaneous model was that tumors grew faster
and became larger within a shorter time frame. The large subcutaneous
tumors protruded from the body and sometimes made it difficult to
position the mice within the radiofrequency coil. Mice had to be sac-
rificed earlier, which may not allow enough time for metastasis to occur
or for longer-term monitoring in future studies. For these reasons, we
selected the intranodal model.
Much of our current understanding of the metastatic process has
come from the use of various in vivo imaging modalities that have
provided us with the ability to visualize different steps in the meta-
static process. Each modality has its strengths but also its limitations
imposed by technological constraints. Optical techniques, such as
bioluminescence imaging, while sensitive to small numbers of cells
(detection limits of 1000 cells), are limited by the penetration of light
through optically opaque tissues and are also seriously limited by spa-
tial resolution, even in mice [36]. With surgical exposure, optical mi-
croscopic methodologies such as intravital video microscopy can
achieve single-cell detection; however, the small fields of view of this
technique can only allow examination of a small fraction of the over-
all target organ, and individual animals can typically only be followed
for short periods of time, e.g., hours [23]. Computed tomography
can produce images of the entire mouse anatomy at high spatial res-
olution (in the order of ∼50 μm) but has poor soft tissue contrast,
and there are no current computed tomography contrast agents that
allow cell tracking [37]. Positron emission tomography and single-
photon emission computed tomography are high-sensitivity imaging
techniques capable of detecting small numbers of cells [37] (hun-
dreds) within the entire organism but have low spatial resolution,
making it difficult to differentiate small groups of cells within target
organs. High-frequency US (20 to 60 MHz) can produce images of
high spatial (∼50 μm) and temporal resolution, but the detection of
tumors by US is limited by the penetration of high-frequency sound
waves in tissue and by bone/air–tissue interfaces that are not echo-
genically accessible [23].
Standard lymphatic MRI is limited to the detection of nodes that
are enlarged and/or irregular [38]. This is a pitfall, because micro-
metastases can often be found in normal-sized and shaped nodes
and because things other than malignancy may cause enlarged nodes.
The use of contrast agents for MRI has improved visualization of
nodes. Both iron- and gadolinium (Gad)-based contrast agents are
currently undergoing testing to increase the use of this imaging mo-
dality for lymph diagnoses [39,40]. Iron oxide nanoparticles have
been used to detect metastases in lymph nodes since the late 1990s,
and some agents (i.e., USPIO) are in clinical trial [41,42]. Iron-based
agents are administered intravenously and slowly accumulate in the
lymph-node macrophages. In malignant nodes, the normal tissue ap-
pears with low signal and the metastatic tissue appears unchanged.
False negatives may result if there is enough normal tissue taking up
iron to cause the whole node to appear black because of blooming,
effectively hiding metastatic tissue. In addition, reactive nodes contain-
ing primarily lymphocytes, which do not take up iron, may result in
false positives [38]. Gad-based agents have been used to improve the
ability to visualize lymph nodes [43]. With Gad-based agents, normal
node tissue appears bright in the images, whereas metastatic tissue re-
mains unchanged [38]. Neither iron- nor Gad-based agents provide
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direct visualization of cancer cells in nodes; both methods work by
changing the signal intensity of normal nodal tissue.
Our novel approach to cellular MRI allowed for cell detection of as
few as 100 MPIO-labeled cells within the lymph node, with injec-
tions of larger cell numbers producing increasingly obvious regions
of signal void. This success in detecting small numbers of MPIO-
labeled cells within the mouse lymph nodes in vivo is the result of
achieving simultaneously high-resolution and high SNR images of
the mouse body. A significant advancement that has allowed us to
do this has been the implementation and optimization of the FIESTA
pulse sequence for this microimaging application. This pulse sequence
is extremely sensitive to the presence of cellularly compartmentalized
iron, but possesses high SNR efficiency. These two characteristics con-
fer an advantage over the more conventional T2- and T2*-weighted
pulse sequences used for imaging iron-labeled cells by most other
groups [44–47]. In addition to pulse sequence optimization, improve-
ments in MR hardware, specifically our implementation of high-
performance gradient coil technology, is a significant factor in our
successful demonstration of cell sensitivity. The higher intrinsic SNR
and resolution afforded by these optimized pulse sequence and hard-
ware components are the chief contributing factors that have allowed
us to achieve low-level in vivo cell detection in the lymphatics while still
using low field strengths that are clinically applicable.
Often, it is desired not only to detect small numbers of cells but
also to track their fate over time. A potential limitation of the in vitro
labeling and tracking schemes is the loss of cell detection that may be
expected to occur with cell division and dilution of the iron label.
Our in vitro studies performed to assess the iron concentration in
dividing cells showed that intracellular iron disappears from dividing
B16F10 cells within 5 days after labeling in culture. This agrees with
previous in vitro studies, which showed that cell division and metab-
olism of biodegradable SPIO agents leads to the loss of sufficient iron
for HeLa cell detection within five to eight generations [48]. Despite
what has been observed in vitro, our results show that image contrast
due to MPIO-labeled cells persists for as long as 22 days in develop-
ing melanomas. When 10,000 iron-labeled cells were implanted,
images at day 1 showed a large focal region of signal loss. Over time,
this focal signal loss became dispersed throughout the developing
tumor. In the last scan, on day 22, signal loss persisted within the
tumor. It is unlikely that the regions of signal loss dispersed through-
out the large tumors represent necrosis because signal loss was not ob-
served in tumors when unlabeled cells were implanted. In addition,
our pathology report indicated that, when there was tumor necrosis,
there was also hemorrhage. We have previously shown that hemor-
rhagic necrosis appears with increased signal intensity on FIESTA
images [49]. Signal hyperintensity, likely due to necrosis and edema,
was observed in FIESTA images of the larger tumors in mice imaged
at day 22 postinjection. This persistent contrast may indicate hetero-
geneity in cell proliferation, division of the magnetic particles be-
tween dividing cells, and/or cell death within the tumor and may
suggest an advantage for the use of the biologically inert MPIO for
cellular MRI of rapidly dividing cells.
We observed other interesting examples of the persistence of signal
loss. When 100 iron-labeled cells were implanted, the pattern of sig-
nal loss was consistent over time. In these cases, there was no tumor
growth, so it is likely that this represents the presence of iron-labeled,
nonproliferative cells in the node. In one case, when 1000 iron-
labeled cells were implanted, the focal region of signal loss observed
on day 1 appeared unchanged as the node clearly expanded around
it. The simplest interpretation of this observation might be that the
iron-labeled cells remain in the original site of implantation while
unlabeled cells proliferate. We know that the MPIO does not prevent
or impair cancer cell division, from routine cell proliferation assays
(data not shown). An alternative interpretation is that only a very
small population of the implanted cells proliferate to form the tumor
cell mass. This is plausible because tumor growth with this low cell
number is rather unpredictable. In half of the mice, implanted with
1000 iron-labeled cells, no tumors were developed at all. It is well
known that in experimental models, the number of cancer cells in-
jected or implanted is a major factor in tumor incidence and growth
rates. In summary, our data show that, in a complex in vivo tumor
system, the contrast from iron-labeled cells can persist for much lon-
ger than would be predicted by in vitro cell division assays.
One remaining challenge is the ability to access and label tumor
cells in situ within lymphatics and other organs. Our future studies
will investigate a double-contrast approach by combining iron-based
contrast agents for labeling cancer cells (negative contrast) with posi-
tive contrast agents for enhancing the lymphatic tissues and vessels.
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